# A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.

> **NCT06075615** · — · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** dacomitnib

## Key facts

- **NCT ID:** NCT06075615
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09-30
- **Primary completion:** 2026-09-07
- **Final completion:** 2026-09-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2025-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06075615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06075615, "A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06075615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*